U.S. Health Care REITs Stock News

Why Sotera Health is back in focus Goldman Sachs has initiated coverage of Sotera Health (SHC), just as the company reports first quarter 2026 earnings that topped revenue and profit expectations and gains clarity on Ethylene Oxide related legal exposures. See our latest analysis for Sotera Health. The recent 1 day share price return of 4.22% to US$16.53, alongside a 90 day share price return of 18.75% and 1 year total shareholder return of 34.39%, points to momentum building as investors...

In recent days, Quest Diagnostics has attracted favorable attention from Wall Street, with analysts issuing 9 buy and 9 hold ratings and no sell calls, reflecting confidence in its broad portfolio of diagnostic testing and healthcare services across the United States. This cluster of positive opinions highlights how Quest’s diversified offering and perceived financial resilience are shaping analyst views on its role in an evolving healthcare landscape. We’ll now examine how this upbeat...

Fox Corporation and the National Football League previously announced a multi-year agreement to bring an extensive slate of live NFL games and original football programming to Fox’s linear, streaming and ad-supported platforms in Mexico starting with the 2026 season. This expansion into Mexico deepens Fox’s relationship with premium live sports while broadening its reach across Latin American audiences and digital services like FOX One and Tubi. Next, we’ll examine how adding comprehensive...

Event context for ERock (EROC) ERock (EROC) is on investor radars after fresh attention on its modular power systems business for data centers, utilities, and commercial clients. The stock last closed at US$21.50 and has a market cap around US$4.71b. See our latest analysis for ERock. With year to date share price returns at 0.00%, the recent focus on ERock’s modular power systems is putting more weight on future execution and risk expectations than on past trading momentum. If this kind of...

Wondering whether Fastly at around US$18.63 is still offering value or if most of the opportunity is already priced in? This breakdown will help you frame the stock through a valuation lens. The share price has pulled back, with Fastly down 10.3% over the last week and 9.2% over the last month, even after a strong 82.8% year to date return and 130.6% return over the past year. These moves come as Fastly remains in focus for investors watching the broader software sector and reassessing risk...

VeriSign overview and recent share performance VeriSign (VRSN) has drawn investor attention recently, with the stock roughly flat over the past month, up about 20% in the past 3 months and 18% year to date. Over the past year, the total return stands at about 3%, while the 3 year and 5 year total returns are approximately 29% and 31%. These figures offer useful context before you look at earnings and valuation. See our latest analysis for VeriSign. While the share price is around $283.89...

Shareholders at nLIGHT's 2026 Annual Meeting voted against the board's proposed executive compensation plan. The failed "Say on Pay" vote signals clear pushback on how leadership at NasdaqGS:LASR is being rewarded. This outcome raises fresh questions around governance priorities and executive alignment with shareholder interests. nLIGHT, listed as NasdaqGS:LASR, develops high power semiconductor and fiber laser solutions for industrial, defense, and other applications. For investors...

If you are wondering whether Truist Financial's share price still offers value at current levels, the next step is to look closely at what that price actually implies. The stock recently closed at US$49.43, with returns of 2.7% over the past week, 0.7% over the past month, a small decline of 0.6% year to date, and gains of 26.9% over 1 year, 78.0% over 3 years, and 9.7% over 5 years. Recent coverage has focused on Truist Financial as a large U.S. bank stock that remains in focus for...

Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending exclusivity through 2041. See our latest analysis for Zevra Therapeutics. The Orange Book patent move has arrived alongside strong momentum, with Zevra’s share price delivering a 63.79% year to date return and a 31.22% 90 day share price return. The 3 year total shareholder return of 134.71%...

If you are wondering whether Fair Isaac at around US$1,225 per share looks expensive or attractive, the answer depends heavily on how you think about value in the first place. The stock has been volatile recently, with a 7 day move of around 2.1% lower, an 8.8% gain over the past month, a decline of 25.4% year to date, and a 31.4% decline over the last year, set against longer term gains of 52.8% over 3 years and 145.3% over 5 years. Recent coverage has focused on how Fair Isaac fits into...

Perrigo (NYSE:PRGO) announced the immediate resignation of CEO and President Patrick Lockwood-Taylor following a Board determination of conduct inconsistent with the company’s Code of Conduct and core values. The company stated the issue is unrelated to Perrigo’s operations or financial reporting. Board member Albert A. Manzone has been appointed Interim CEO while a comprehensive search for a permanent CEO is underway. Perrigo’s leadership change comes at a time when the stock has faced...

SailPoint (SAIL) has opened Q1 2027 with revenue of US$280.1 million, a loss of US$74.7 million in net income and basic EPS of US$0.13 loss, while the trailing twelve months show revenue of US$1.1 billion and a total EPS loss of US$0.28. Over recent quarters the company has seen revenue move from US$230.5 million in Q1 2026 to US$280.1 million in Q1 2027, alongside quarterly EPS losses in a range between US$0.42 and US$0.02. The latest print keeps the focus firmly on how quickly revenue...

Wondering whether Xylem's share price still reflects fair value, or if the recent moves have opened up a mispricing worth your attention. The stock recently closed at US$110.87, with a small 0.5% gain over the last 7 days, a 2.5% decline over the past month, and a year to date fall of 19.1% that leaves the 1-year return down 12.6% and the 3-year and 5-year returns at 3.8% and 0.3% respectively. Recent news coverage has focused on Xylem's role in the broader capital goods sector and ongoing...

Vitesse Energy, Inc. ( NYSE:VTS ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is usually set...

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

If you are wondering whether IES Holdings at around US$726 per share still offers value, or if most of the opportunity is already priced in, this article explains what the current price could mean for you. The stock has recently shown strong momentum, with returns of 3.0% over the last 7 days, 8.9% over the last 30 days, 78.5% year to date, 169.3% over 1 year, and a very large gain over 3 and 5 years. Recent coverage of IES Holdings has focused on its sharp share price performance and...

Wondering if AngloGold Ashanti at around US$84.43 is still offering value after a strong run, or if the easy gains are behind it. The stock has pulled back recently, down 8.1% over the last week and 21.1% over the last month, yet it still shows a 97.5% return over the past year and a very large 3 year return, with a 362.6% return over 5 years. Recent price moves sit against a backdrop of ongoing interest in gold producers and periodic shifts in risk appetite across the sector. For AngloGold...

Whether Federated Hermes stock still offers value at around US$57.65 depends on how you consider its fundamentals and price together. The stock closed at US$57.65, with returns of 2.7% over 7 days, 3.0% over 30 days, 10.1% year to date, 39.6% over 1 year, 75.3% over 3 years and 113.7% over 5 years. These figures may influence how you think about both its growth potential and risk. This article is intended to provide ongoing coverage of Federated Hermes, giving investors context that goes...

In late May and early June 2026, REalloys Inc. announced non-binding agreements with Patriot Exploration & Mining and Ramaco Resources to evaluate priority access to U.S. rare earth feedstocks, including above-ground Appalachian resources and coal-hosted materials from Wyoming’s Brook Mine. This emerging network of unconventional, domestically sourced feedstocks is central to REalloys’ effort to build a compliant, defense-focused rare earth processing and magnet manufacturing platform ahead...

Context for Patrick Industries stock move Patrick Industries (PATK) shares have softened recently, with the stock down about 8% over the past month and about 24% over the past 3 months. This has prompted fresh attention on its underlying fundamentals. See our latest analysis for Patrick Industries. The recent 1-day share price return of 3.30% contrasts with a decline in the 30-day and 90-day share price returns. However, the 3-year and 5-year total shareholder returns remain positive,...

If you are wondering whether Installed Building Products at around US$206 is still a reasonable entry point or starting to look stretched, the valuation metrics behind the stock are worth a closer look. The stock has been fairly mixed recently, with a 0.8% gain over the last 7 days, a decline of 6.3% over the last 30 days, and a larger fall of 23.0% year to date, even though the 1 year, 3 year and 5 year returns sit at 19.3%, 78.5% and 96.7% respectively. Recent coverage has focused on how...

Bilibili (BILI) has drawn attention after recent trading left the stock down about 20% over the past month and roughly 31% over the past 3 months, prompting investors to reassess its current valuation. See our latest analysis for Bilibili. At a share price of $17.61, Bilibili’s short term momentum has clearly cooled, with the stock down over the past week and month. The 3 year total shareholder return remains slightly positive, in contrast with a much weaker 5 year record. If you are looking...

Wondering if MSCI is priced for perfection or still offers value at current levels? With the stock trading around US$607.54, this article focuses squarely on what you are paying versus what you might be getting. MSCI has been choppy in the short term, with the share price down 3.6% over the past week but up 3.8% over the past month and 7.5% year to date. The 1 year return sits at 10.4%, and the 3 year and 5 year returns are 31.3% and 29.7% respectively. These moves have been set against...

Coca-Cola Consolidated (COKE) recently moved in step with a broad beverage sector rally, as peers also posted gains. This points to sector sentiment, rather than company specific developments, as the main driver of the stock. See our latest analysis for Coca-Cola Consolidated. At a share price of $185.09, Coca-Cola Consolidated has seen a 23.53% year to date share price return and a 371.13% five year total shareholder return, suggesting long term momentum alongside some recent volatility as...